Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.

@article{Altorki2003CelecoxibAS,
  title={Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.},
  author={Nasser Khaled Altorki and Roger S Keresztes and Jeffrey L. Port and Daniel M. Libby and Robert J. Korst and Douglas B. Flieder and Cathy A. Ferrara and David F. Yankelevitz and Kotha Subbaramaiah and Mark W Pasmantier and Andrew J. Dannenberg},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2003},
  volume={21 14},
  pages={2645-50}
}
PURPOSE Preclinical studies suggest that treatment with a selective cyclo-oxygenase-2 (COX-2) inhibitor may augment the antitumor effects of chemotherapy. In this study, patients with non-small-cell lung cancer (NSCLC) were preoperatively treated with celecoxib in combination with chemotherapy. End points were toxicity, response rates, and measurement of intratumoral levels of prostaglandin E2 (PGE2). METHODS In this phase II trial, 29 patients with stages IB to IIIA NSCLC were treated with… CONTINUE READING
54 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 54 extracted citations

Similar Papers

Loading similar papers…